We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CytoGenix Completes synDNA™ Supply Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CytoGenix Completes synDNA™ Supply Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

CytoGenix, Inc. announced completion of the first Supply Agreement to provide DNA products to one of its customers. Under the Agreement, the customer will purchase its entire requirements of DNA products from CytoGenix for the term of the Agreement.

The customer will provide CytoGenix with flexible one year and quarterly forecasts representing the customer’s needs for multiple key DNA constructs of the type and quantity of DNA products that the customer expects to purchase in each of the next four calendar quarters.

Dr. Yin Chen, Chief Scientific Officer, comments, “Customer recognition of the advantages of our cell-free DNA production platform contrasted with plasmid DNA derived from bacteria is a major contributing factor in attracting this type of repetitive commitment to purchase our synDNATM products.”

Dr. Frederic Kendirgi, Senior Scientist overseeing the Company’s DNA production platforms, notes, “This Agreement advances the ongoing relationship with our customer, acknowledging our ability to produce and supply DNA material of custom quality and in a timely manner per the customer’s request and expectation. We expect this agreement to demonstrate our commitment to foster productive and long term relationships with clients.”

Malcolm Skolnick, CEO, states, “This Agreement is a step in the Company’s goal toward selling synDNA™ products in the therapeutic market as a replacement for plasmid based DNA products. We will continue our efforts to expand our synDNA™ sales and conclude similar agreements with additional customers.”